US40131M1099 - Common Stock
GUARDANT HEALTH INC
NASDAQ:GH (5/2/2024, 7:00:01 PM)
After market: 18.52 -0.06 (-0.32%)18.58
+0.32 (+1.75%)
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,793 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The firm has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company’s GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.
GUARDANT HEALTH INC
3100 Hanover Street
Palo Alto CALIFORNIA 94063
P: 18556988887
CEO: Helmy Eltoukhy
Employees: 1793
Website: https://guardanthealth.com/
/PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the nomination of...
The companies are working to detect colon cancer and precancerous markers in blood and/or stool.
Here you can normally see the latest stock twits on GH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: